▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #205 by analyst upside · 2026-11-12
IMMP
Immutep Limited
Healthcare · Market Cap $26M · P/E 0x
ANALYST PRICE TARGET
+742.7%
implied upside to consensus target
Current Price $3.56
Consensus Target $30.0
Bull Target $30.0
Bear Target $30.0
Analysts Covering 1
ANALYST CONSENSUS - STRONG BUY
Strong Buy
1
Buy
0
Hold
0
Sell
0
52-Week Low $2.66
52-Week High $70.6
YTD Return -94.0%
FUNDAMENTALS
Market Cap $26M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-7.51
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $20M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $2.66
52-Week High $70.6
Current Price $3.56
Bear Target $30.0
Bull Target $30.0
● Now $3.56 ● Target $30.0
TRADING DATA
Avg Volume 20K
YTD Return -94.0%
Analyst Count 1
Consensus Strong Buy
Upside to Target +742.7%
Last Updated 2026-11-12

ANALYST SUMMARY

Immutep Limited (IMMP) is currently trading at $3.56 with a Wall Street consensus price target of $30.0, implying potential upside of 742.7% over the next 12 months. 1 analysts currently cover IMMP, with a consensus rating of Strong Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $30.0, while the most cautious has a target of $30.0.

IMMP operates in the Healthcare sector with a market capitalisation of $26M. The stock is down 94.0% year-to-date and is currently trading near the lower end of its 52-week range of $2.66 – $70.6.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

NCEL +721.4%
NewcelX Ltd.
$16M · P/E 5.6x · Hold
VXRT +800.9%
Vaxart, Inc.
$90M · P/E 2.8x · Buy
ETST +1036.4%
Earth Science Tech, Inc.
$25M · P/E 8.8x · Hold
HIND +462.6%
Vyome Holdings, Inc.
$11M · P/E 0.9x · Buy
DWTX +1086.4%
Dogwood Therapeutics, Inc.
$45M · P/E 0.1x · Strong Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for IMMP, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Maxim Group ↑ Upgrade
Hold → Buy 2026-06-17 28% win rate (40 calls)
Citizens ↓ Downgrade
Market Outperform → Market Perform 2026-03-13 Building track record
Baird ↓ Downgrade
Outperform → Neutral 2026-03-13 Building track record
Citizens ● Initiated
Market Outperform 2026-02-23 Building track record
Citizens ● Initiated
Market Outperform 2026-02-17 Building track record
Baird - Reiterated
Outperform → Outperform 2024-11-15 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
48
out of 100
Coverage depth
5/30
Consensus clarity
8/30
Vote unanimity
25/25
Rating stability
10/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →